What is Iksuda Therapeutics?
Founded in 2007 and headquartered in Newcastle upon Tyne, UK, Iksuda Therapeutics is dedicated to advancing cancer treatment through its innovative Antibody Drug Conjugate (ADC) technology. The company's focus lies in creating ADCs that are more stable and potent than existing options, utilizing its proprietary PermaLink® conjugation platform. This platform is combined with a suite of highly potent cytotoxic payloads, designed to maximize antitumor activity and improve patient outcomes, particularly for tumors resistant to current therapies.
How much funding has Iksuda Therapeutics raised?
Iksuda Therapeutics has raised a total of $47M across 1 funding round:
Unspecified
$47M
Unspecified (2021): $47M with participation from Mirae Asset Capital Co,Ltd, Celltrion, and Premier Partners
Key Investors in Iksuda Therapeutics
Mirae Asset Capital Co,Ltd
Mirae Asset Capital Co Ltd is an investment banking firm based in Seoul, South Korea, likely focusing on strategic capital allocation for growth-stage companies.
Celltrion
Celltrion is a leading South Korean biopharmaceutical company specializing in biosimilars and innovative drugs, suggesting a strategic interest in therapeutic advancements.
Premier Partners
Premier Partners, based in the Netherlands, offers a range of financial and advisory services, indicating a potential role in facilitating strategic financial growth for Iksuda Therapeutics.
What's next for Iksuda Therapeutics?
The recent major strategic investment signals a pivotal stage for Iksuda Therapeutics, likely enabling the company to accelerate its pipeline development and clinical trials. This capital infusion is expected to bolster its research and development efforts, potentially leading to expanded therapeutic applications and strategic partnerships within the oncology sector. The company's focus on next-generation ADCs positions it to address unmet needs in cancer care, aiming for enhanced efficacy and patient well-being.
See full Iksuda Therapeutics company page
